Lipocine Inc. Files 8-K Report
Ticker: LPCN · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
TL;DR
Lipocine filed an 8-K on 3/28/24, standard reporting.
AI Summary
Lipocine Inc. filed an 8-K on March 28, 2024, reporting on other events and financial statements. The filing does not contain specific details about new material events or financial figures within the provided text, but indicates a standard reporting update.
Why It Matters
This filing serves as a standard disclosure for Lipocine Inc., informing investors about significant corporate events or financial updates as required by the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not appear to contain any immediately disclosed negative or positive material information.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- March 28, 2024 (date) — Date of Report
- 001-36357 (other) — Commission File Number
- 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Lipocine Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 28, 2024.
When was this 8-K report filed by Lipocine Inc.?
This 8-K report was filed on March 28, 2024.
What is Lipocine Inc.'s principal executive office address?
Lipocine Inc.'s principal executive office is located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
What is the Commission File Number for Lipocine Inc.?
The Commission File Number for Lipocine Inc. is 001-36357.
Does the filing indicate any former company name or address changes?
The filing states 'Not Applicable' for former company name or address changes since the last report.
Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-03-28 06:26:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 53KB
- form8-k_001.jpg (GRAPHIC) — 4KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-011600.txt ( ) — 284KB
- lpcn-20240328.xsd (EX-101.SCH) — 3KB
- lpcn-20240328_lab.xml (EX-101.LAB) — 33KB
- lpcn-20240328_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On March 28, 2024, the Company issued a press release announcing positive topline results from our LPCN 1148 Phase 2 Study in patients with cirrhosis. The press release is filed as Exhibits 99.1 and is incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed with this report: Exhibit No. Description 99.1 Press Release announcing "Lipocine Announces Positive Topline Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: March 28, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer